Therapy News and Research

RSS

NMT Medical reports $2.6 million net income for second-quarter 2010

NMT Medical, Inc., an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures, today announced financial results for the quarter ended June 30, 2010.

30 Jul 2010

ACADIA initiates new pimavanserin Phase III trial for Parkinson's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has initiated a new Phase III trial designed to evaluate the efficacy, tolerability and safety of pimavanserin as a treatment for patients with Parkinson's disease psychosis (PDP).

30 Jul 2010

Geron second-quarter net loss decreases to $17.0 million

Geron Corporation today reported financial results for the three and six months ended June 30, 2010.

30 Jul 2010

TNF blockers may increase the risk of malignancy in children

The Food and Drug Administration (FDA) received reports of malignancies in children using tumor necrosis factor a (TNF) blockers, raising concerns of an associated risk and prompting an investigation.

29 Jul 2010

$Postmenopausal women with diabetes taking TZDs at increased fracture risk$

Postmenopausal women with diabetes taking TZDs at increased fracture risk

Postmenopausal women with diabetes taking thiazolidinediones (TZDS), including rosiglitazone and pioglitazone, may be at increased risk for fractures according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). Men with diabetes taking both loop diuretics and TZDs may also be at increased risk of fractures.

29 Jul 2010

Gentiva Health Services second-quarter total net revenues increase 4% to $297.1 million

Gentiva Health Services, Inc., a leading provider of home health and hospice services, today reported second quarter 2010 results.

29 Jul 2010

BCBSNC receives CEO Cancer Gold Standard certification

Blue Cross and Blue Shield of North Carolina has received CEO Cancer Gold Standard accreditation, recognizing the organization's commitment to reducing the risk of cancer for employees and their families by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment.

29 Jul 2010

Celgene second-quarter non-GAAP total revenue increases 36% to $850 million

Celgene Corporation announced non-GAAP net income of $323.3 million, or non-GAAP diluted earnings per share of $0.69 for the quarter ended June 30, 2010. Non-GAAP net income for the second quarter of 2009 was $216.0 million or non-GAAP diluted earnings per share of $0.46.

29 Jul 2010

Antigenics second-quarter net loss attributable to common stockholders decreases to $5.2 million

Antigenics Inc. reported today its results for the quarter ended June 30, 2010.

29 Jul 2010

Natus Medical second-quarter revenue increases to $52.7 million

Natus Medical Incorporated today announced financial results for the three and six months ended June 30, 2010.

29 Jul 2010

First Edition: July 29, 2010

In today's headlines, a new poll shows opposition to health reform declining, and Peter Orszag makes his exit as budget chief -- still pressing lawmakers to make tough budget choices while implementing the new law.

29 Jul 2010

AVEO second-quarter total revenues increase to $15.6 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.

29 Jul 2010

Bionovo receives EMA final guidance for advancing Menerba to Phase 3 clinical trials

Bionovo, Inc. announced today that it has received final guidance from the European Medicines Agency (EMA) in order to advance Menerba, the company's lead drug candidate for menopausal symptoms, to Phase 3 clinical trials in Europe. The guidance defines the clinical and regulatory pathway to a European marketing authorization for Menerba.

29 Jul 2010

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

Abraxis BioScience, Inc., a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.

29 Jul 2010

SIR offers five-day course that covers all aspects of acute stroke management

Catheter Lysis of Thromboembolic Stroke -an intensive five-day course offered by the Society of Interventional Radiology Oct. 24-28 in Dallas, Texas-provides interventional radiologists, neurointerventionalists, vascular neurologists and fellows-in-training with the unique educational opportunity to review, observe and discuss all aspects of acute stroke management.

29 Jul 2010

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

Angiotech Pharmaceuticals, Inc. and partner Athersys, Inc. announced positive results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction, more commonly referred to as a heart attack.

29 Jul 2010

Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and indicated no significant safety concerns for the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 70 well-known urology investigative sites throughout the U.S.

29 Jul 2010

Advaxis provides update on survival information from ADXS11-001 phase 1 trial in cervix cancer

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.

29 Jul 2010

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Dendreon Corporation announced today the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer. The manuscript is published in the July 29, 2010 issue of the journal.

29 Jul 2010

Intensive chemotherapy may benefit elderly patients with acute myeloid leukemia

The prognosis for nearly three-quarters of elderly patients on intensive chemotherapy for acute myeloid leukemia (AML) is poor, with a median survival of less than six months, according to a study published online today in Blood, the journal of the American Society of Hematology. AML is the most common form of acute leukemia among adults and is a rapidly growing cancer of the bone marrow that requires immediate treatment. The average age at diagnosis is 67, and more than 12,000 people will be diagnosed with AML this year (according to the National Cancer Institute).

29 Jul 2010

Therapy News and Research

NMT Medical reports $2.6 million net income for second-quarter 2010

ACADIA initiates new pimavanserin Phase III trial for Parkinson's disease psychosis

Geron second-quarter net loss decreases to $17.0 million

TNF blockers may increase the risk of malignancy in children

Postmenopausal women with diabetes taking TZDs at increased fracture risk

Gentiva Health Services second-quarter total net revenues increase 4% to $297.1 million

BCBSNC receives CEO Cancer Gold Standard certification

Celgene second-quarter non-GAAP total revenue increases 36% to $850 million

Antigenics second-quarter net loss attributable to common stockholders decreases to $5.2 million

Natus Medical second-quarter revenue increases to $52.7 million

First Edition: July 29, 2010

AVEO second-quarter total revenues increase to $15.6 million

Bionovo receives EMA final guidance for advancing Menerba to Phase 3 clinical trials

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

SIR offers five-day course that covers all aspects of acute stroke management

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia

Advaxis provides update on survival information from ADXS11-001 phase 1 trial in cervix cancer

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Intensive chemotherapy may benefit elderly patients with acute myeloid leukemia

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News